These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 25267662)
41. Pharmacokinetics of colistin methanesulfonate (CMS) in healthy Chinese subjects after single and multiple intravenous doses. Zhao M; Wu XJ; Fan YX; Zhang YY; Guo BN; Yu JC; Cao GY; Chen YC; Wu JF; Shi YG; Li J; Zhang J Int J Antimicrob Agents; 2018 May; 51(5):714-720. PubMed ID: 29305956 [TBL] [Abstract][Full Text] [Related]
42. Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: Dose is critical. Sorlí L; Luque S; Li J; Campillo N; Danés M; Montero M; Segura C; Grau S; Horcajada JP J Infect; 2019 Sep; 79(3):253-261. PubMed ID: 31265867 [TBL] [Abstract][Full Text] [Related]
47. Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing. Jitmuang A; Nation RL; Koomanachai P; Chen G; Lee HJ; Wasuwattakul S; Sritippayawan S; Li J; Thamlikitkul V; Landersdorfer CB J Antimicrob Chemother; 2015; 70(6):1804-11. PubMed ID: 25698772 [TBL] [Abstract][Full Text] [Related]
48. Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections. Yapa SWS; Li J; Porter CJ; Nation RL; Patel K; McIntosh MP Antimicrob Agents Chemother; 2013 Oct; 57(10):5087-95. PubMed ID: 23917323 [TBL] [Abstract][Full Text] [Related]
49. Colistin pharmacokinetics: the fog is lifting. Couet W; Grégoire N; Marchand S; Mimoz O Clin Microbiol Infect; 2012 Jan; 18(1):30-9. PubMed ID: 21988234 [TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. Li J; Milne RW; Nation RL; Turnidge JD; Smeaton TC; Coulthard K J Antimicrob Chemother; 2004 May; 53(5):837-40. PubMed ID: 15044428 [TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Couet W; Grégoire N; Gobin P; Saulnier PJ; Frasca D; Marchand S; Mimoz O Clin Pharmacol Ther; 2011 Jun; 89(6):875-9. PubMed ID: 21544080 [TBL] [Abstract][Full Text] [Related]
52. Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B. Rigatto MH; Oliveira MS; Perdigão-Neto LV; Levin AS; Carrilho CM; Tanita MT; Tuon FF; Cardoso DE; Lopes NT; Falci DR; Zavascki AP Antimicrob Agents Chemother; 2016 Apr; 60(4):2443-9. PubMed ID: 26856846 [TBL] [Abstract][Full Text] [Related]
53. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Kasiakou SK; Michalopoulos A; Soteriades ES; Samonis G; Sermaides GJ; Falagas ME Antimicrob Agents Chemother; 2005 Aug; 49(8):3136-46. PubMed ID: 16048915 [TBL] [Abstract][Full Text] [Related]
54. Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study. Markou N; Fousteri M; Markantonis SL; Zidianakis B; Hroni D; Boutzouka E; Baltopoulos G J Antimicrob Chemother; 2012 Oct; 67(10):2459-62. PubMed ID: 22790220 [TBL] [Abstract][Full Text] [Related]
55. Colistin: how should it be dosed for the critically ill? Landersdorfer CB; Nation RL Semin Respir Crit Care Med; 2015 Feb; 36(1):126-35. PubMed ID: 25643276 [TBL] [Abstract][Full Text] [Related]
56. Optimal empiric treatment for KPC-2-producing Klebsiella pneumoniae infections in critically ill patients with normal or decreased renal function using Monte Carlo simulation. Wang G; Yu W; Cui Y; Shi Q; Huang C; Xiao Y BMC Infect Dis; 2021 Mar; 21(1):307. PubMed ID: 33771113 [TBL] [Abstract][Full Text] [Related]
57. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Yapa SWS; Li J; Patel K; Wilson JW; Dooley MJ; George J; Clark D; Poole S; Williams E; Porter CJ; Nation RL; McIntosh MP Antimicrob Agents Chemother; 2014 May; 58(5):2570-9. PubMed ID: 24550334 [TBL] [Abstract][Full Text] [Related]
58. Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses. Marchand S; Lamarche I; Gobin P; Couet W J Antimicrob Chemother; 2010 Aug; 65(8):1753-8. PubMed ID: 20507861 [TBL] [Abstract][Full Text] [Related]
59. Determination by LC-MS/MS of colistins A and B in plasma and ultrafiltrate from critically ill patients undergoing continuous venovenous hemodiafiltration. Leporati M; Bua RO; Mariano F; Carignano P; Stella M; Biancone L; Vincenti M Ther Drug Monit; 2014 Apr; 36(2):182-91. PubMed ID: 24216535 [TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetics of Colistin Methansulphonate (CMS) and Colistin after CMS Nebulisation in Baboon Monkeys. Marchand S; Bouchene S; de Monte M; Guilleminault L; Montharu J; Cabrera M; Grégoire N; Gobin P; Diot P; Couet W; Vecellio L Pharm Res; 2015 Oct; 32(10):3403-14. PubMed ID: 26040660 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]